Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML.

J Exp Med · 2019 · PMC6446874 · PMID 30890554

Europe PMC DOI

hedged sentence

0.0503

closest p · 1.0× alpha

0.0503

boldest claim

The sentences

a strong trendP = 0.0503so close (0.05 < p ≤ 0.1)

56%), with an adverse HR for OS (HR, 3.94; CI, 1.00–1.55) and a strong trend for a lower survival advantage by log-rank analysis (P = 0.0503; Fig. 4 c ).

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.